Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.

Alzheimer’s disease Dementia Quality of life Systematic literature review

Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
18 11 2020
Historique:
received: 16 03 2020
accepted: 06 11 2020
entrez: 19 11 2020
pubmed: 20 11 2020
medline: 25 6 2021
Statut: epublish

Résumé

Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions. To provide an overview of which quality of life instruments are being used to assess HR-QoL in people with predementia AD, MCI or dementia; and, to summarise their reported HR-QoL levels at each stage of the disease and by type of respondent. We systematically searched for and reviewed eligible studies published between January 1990 and the end of April 2017 which reported HR-QoL for people with predementia AD, MCI or dementia. We only included instruments which are preference-based, allowing index scores/utility values to be attached to each health state they describe based on preferences obtained from population surveys. Summary results were presented by respondent type (self or proxy), type of instrument, geographical location and, where possible, stage of disease. Health state utility values derived using the EuroQoL 5-Dimensions (EQ-5D) were meta-analysed by pooling reported results across all studies by disease severity (MCI, mild, mild to moderate, moderate, severe dementia, not specified) and by respondent (person with dementia, carer, general public, not specified), using a fixed-effects approach. We identified 61 studies which reported HR-QoL for people with MCI or dementia using preference-based instruments, of which 48 used the EQ-5D. Thirty-six studies reported HR-QoL for mild and/or moderate disease severities, and 12 studies reported utility values for MCI. We found systematic differences between self-rated and proxy-rated HR-QoL, with proxy-rated utility valued being significantly lower in more severe disease states. A substantial literature now exists quantifying the impact of dementia on HR-QoL using preference-based measures, giving researchers and modellers a firmer basis on which to select appropriate utility values when estimating the effectiveness and cost-effectiveness of interventions in this area. Further research is required on HR-QoL of people with preclinical and prodromal AD and MCI, possible differences by type of dementia, the effects of comorbidities, study setting and the informal caregiver's own HR-QoL, including any effect of that on their proxy-ratings.

Sections du résumé

BACKGROUND
Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions.
AIMS
To provide an overview of which quality of life instruments are being used to assess HR-QoL in people with predementia AD, MCI or dementia; and, to summarise their reported HR-QoL levels at each stage of the disease and by type of respondent.
METHODS
We systematically searched for and reviewed eligible studies published between January 1990 and the end of April 2017 which reported HR-QoL for people with predementia AD, MCI or dementia. We only included instruments which are preference-based, allowing index scores/utility values to be attached to each health state they describe based on preferences obtained from population surveys. Summary results were presented by respondent type (self or proxy), type of instrument, geographical location and, where possible, stage of disease. Health state utility values derived using the EuroQoL 5-Dimensions (EQ-5D) were meta-analysed by pooling reported results across all studies by disease severity (MCI, mild, mild to moderate, moderate, severe dementia, not specified) and by respondent (person with dementia, carer, general public, not specified), using a fixed-effects approach.
RESULTS
We identified 61 studies which reported HR-QoL for people with MCI or dementia using preference-based instruments, of which 48 used the EQ-5D. Thirty-six studies reported HR-QoL for mild and/or moderate disease severities, and 12 studies reported utility values for MCI. We found systematic differences between self-rated and proxy-rated HR-QoL, with proxy-rated utility valued being significantly lower in more severe disease states.
CONCLUSIONS
A substantial literature now exists quantifying the impact of dementia on HR-QoL using preference-based measures, giving researchers and modellers a firmer basis on which to select appropriate utility values when estimating the effectiveness and cost-effectiveness of interventions in this area. Further research is required on HR-QoL of people with preclinical and prodromal AD and MCI, possible differences by type of dementia, the effects of comorbidities, study setting and the informal caregiver's own HR-QoL, including any effect of that on their proxy-ratings.

Identifiants

pubmed: 33208190
doi: 10.1186/s13195-020-00723-1
pii: 10.1186/s13195-020-00723-1
pmc: PMC7677851
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

154

Références

BMC Med Res Methodol. 2013 Sep 06;13:110
pubmed: 24011428
Lancet Neurol. 2008 Sep;7(9):812-26
pubmed: 18667359
Appl Health Econ Health Policy. 2017 Jun;15(3):399-412
pubmed: 27882528
Psychol Med. 2014 Mar;44(4):673-83
pubmed: 23521899
Alzheimers Dement. 2016 Mar;12(3):292-323
pubmed: 27012484
Value Health. 2011 Mar-Apr;14(2):390-9
pubmed: 21402307
Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):49-55
pubmed: 16493236
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Pharmacoeconomics. 1996 Oct;10(4):336-55
pubmed: 10163577
Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S2
pubmed: 24565215
N Engl J Med. 2009 May 28;360(22):2302-9
pubmed: 19474427
Alzheimers Dement. 2017 Apr;13(4):374-380
pubmed: 28314660
Dement Neuropsychol. 2017 Oct-Dec;11(4):364-370
pubmed: 29354216
Neurology. 2000;54(11 Suppl 5):S4-9
pubmed: 10854354
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
BMJ Open. 2018 Mar 30;8(3):e019082
pubmed: 29602838
Pharmacoeconomics. 2016 Jul;34(7):645-9
pubmed: 26892973
J R Soc Interface. 2012 Jan 7;9(66):119-26
pubmed: 21653567
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
Dement Geriatr Cogn Disord. 2004;17(3):181-7
pubmed: 14739542
Biomed Res Int. 2014;2014:908915
pubmed: 25089278
Qual Life Res. 2018 May;27(5):1283-1294
pubmed: 29305782
J Alzheimers Dis. 2019;67(2):495-501
pubmed: 30584137
Drugs Aging. 2012 Jan 1;29(1):31-43
pubmed: 22191721
J Neurol Sci. 2002 Nov 15;203-204:29-34
pubmed: 12417353
Value Health. 2018 Apr;21(4):471-481
pubmed: 29680105

Auteurs

Filipa Landeiro (F)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK. filipa.landeiro@ndph.ox.ac.uk.

Seher Mughal (S)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Katie Walsh (K)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Elsbeth Nye (E)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Jasmine Morton (J)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Harriet Williams (H)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Isaac Ghinai (I)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Yovanna Castro (Y)

Global Access, Centre of Excellence, F. Hoffmann-La Roche Ltd, Bldg 1, CH-4070, Basel, Switzerland.

José Leal (J)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Nia Roberts (N)

Bodleian Health Care Libraries, Old Road Campus, University of Oxford, Oxford, OX3 7LF, UK.

Helena Wace (H)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Ron Handels (R)

Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands.
Department of Neurobiology, Care Science and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden.

Pascal Lecomte (P)

Global Head Health Economic Modelling and Methodology, Novartis Pharma AG, 4002, Basel, Switzerland.

Anders Gustavsson (A)

Department of Neurobiology, Care Science and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden.
Quantify Research, Stockholm, Sweden.

Emilse Roncancio-Diaz (E)

Life Sciences, GE Healthcare Life Sciences, Amersham, UK.

Mark Belger (M)

Global Statistical Sciences, Eli Lilly and Company, Indianapolis, IN 46225, USA.

Gurleen S Jhuti (GS)

Global Access, Centre of Excellence, F. Hoffmann-La Roche Ltd, Bldg 1, CH-4070, Basel, Switzerland.

Jacoline C Bouvy (JC)

Science Policy and Research Programme, National Institute for Health and Care Excellence, 10 Spring Gardens, London, SW1A 2BU, UK.

Michele H Potashman (MH)

Value and Access, Biogen, 225 Binney St, Cambridge, MA, 02139, USA.

Antje Tockhorn-Heidenreich (A)

GPORWE International, Eli Lilly and Company, Indianapolis, IN 46225, USA.

Alastair M Gray (AM)

Health Economics Research Centre, Nuffield Department of Population Health, Old Road Campus, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH